JB
Jeffrey Allen Bailey
Director

Jeffrey Allen Bailey insider trades: Aurinia Pharmaceuticals (AUPH) stock buys and sales

Director, Aurinia Pharmaceuticals Last trade Nov 11, 2024 40 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2019
10
Companies
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Jeffrey reports to the SEC

and 4 more companies

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 11, 2024AUPH↓ Sell$38K
Dec 15, 2020BDSI↓ Sell$44K
Sep 23, 2020THQ↑ Buy$10K
Sep 23, 2020THW↑ Buy$10K
Sep 23, 2020HQH↑ Buy$10K
Sep 22, 2020HQL↑ Buy$10K
Nov 15, 2019ALRN↑ Buy$28K
Nov 12, 2019ALRN↑ Buy$11K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other AUPH insiders

Open-market trades in the last 12 months

About Jeffrey Allen Bailey's insider trades

Jeffrey Allen Bailey is a director at Aurinia Pharmaceuticals (AUPH). Since Nov 12, 2019, Jeffrey has reported 6 open-market purchases worth $79K and 2 sales worth $82K on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (21 filings), option exercises (8 filings), shares returned to the company (5 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AUPH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.